Agree, but having 3 (and possibly now 4) stream of revenue are better than 1 and in particular if RAP will offer the same solution as RSH for chronic asthma respiratory management but a big differing point is with RAP's solution the users can choose to just use their smartphone instead of purchasing additional hardware. IMO, this will be a massive point of difference between both solutions not to mention RAP will also have access to the chronic COPD market which is a big sector of the chronic respiratory management.
And I didn't assume the following and IMO this is an important point that has to be addressed before any significant movement in the pps is seen by the market, don't you agree??? Are there even any pre-clinical studies result for this????
"The question I always had with Wheezo is why they require additional clinical trial tested against current physician standard as mentioned by MM for the pharmacy to be "approached", hence I question why they've signed a service agreement without these clinical trial results."
RSH Price at posting:
8.0¢ Sentiment: Hold Disclosure: Not Held
(20min delay)